MoonLake Immunotherapeutics MLTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Long-Lived Assets by Geography | ||||||
| Portugal | $4.21M-6.3% | $4.48M+7.3% | $4.72M+29.1% | $4.77M— | $4.49M— | |
| Switzerland | $2.07M-19.7% | $1.72M-39.7% | $2.01M-27.0% | $2.3M— | $2.58M— | |
| United Kingdom | $3.7M-51.1% | $4.69M-44.9% | $5.66M-40.0% | $6.62M— | $7.57M— | |
| Number of operating leases by Geography | ||||||
| Portugal | 3.5+75.0% | 20.0% | 2— | 2— | 2— | |
| Switzerland | 3.5+75.0% | 20.0% | 2— | 2— | 2— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MoonLake Immunotherapeutics break its business down?
- MoonLake Immunotherapeutics (MLTX) reports long-lived assets by geography across 3 parts — Portugal, Switzerland and United Kingdom. Each is extracted from the segment footnotes and tracked over time.
- Where does MoonLake Immunotherapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MoonLake Immunotherapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.